Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Navid Hasani"'
Autor:
Fatemeh Bazvand, Farhad Salari, Navid Hasani Barzi, Fariba Ghassemi, Anahid Maleki, Afsar Dastjani Farahani, Marjan Imani Fooladi, Naeeme Taslimi Taleghani, Maryam Khoshnoud Shariati, C. Armitage Harper, Mohammadreza Mehrabi Bahar
Publikováno v:
International Journal of Retina and Vitreous, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Purpose To investigate foveal changes in infants with ROP not requiring treatment(nROP) and ROP infants needing treatment (tROP) using a handheld SD-OCT device. Method We performed horizontal SD-OCT scans through the fovea in 156 eyes of 81
Externí odkaz:
https://doaj.org/article/e23a7a299a254c5d9d41371fec4b176d
Autor:
Eren M. Veziroglu, Faraz Farhadi, Navid Hasani, Moozhan Nikpanah, Mark Roschewski, Ronald M. Summers, Babak Saboury
Publikováno v:
Seminars in Nuclear Medicine. 53:426-448
Autor:
Bazvand, Fatemeh, Salari, Farhad, Barzi, Navid Hasani, Ghassemi, Fariba, Maleki, Anahid, Dastjani Farahani, Afsar, Imani Fooladi, Marjan, Taleghani, Naeeme Taslimi, Shariati, Maryam Khoshnoud, Harper III, C. Armitage, Mehrabi Bahar, Mohammadreza
Publikováno v:
International Journal of Retina & Vitreous; 10/18/2023, Vol. 9 Issue 1, p1-12, 12p
Autor:
Ronald M. Summers, Eliot L. Siegel, Faraz Farhadi, Anne Pariser, Navid Hasani, Arman Rhamim, Babak Saboury, Moozhan Nikpanah, Yanji Xu, Michael A. Morris, Elizabeth C. Jones, Michael T. Collins
Publikováno v:
PET Clin
Almost 1 in 10 individuals can suffer from one of many rare diseases (RDs). The average time to diagnosis for an RD patient is as high as 7 years. Artificial intelligence (AI)-based positron emission tomography (PET), if implemented appropriately, ha
Autor:
Michael A. Morris, Sriram S Paravastu, Ronald M. Summers, Arman Rahmim, Faraz Farhadi, Navid Hasani, Mark Roschewski, Fereshteh Yousefirizi, Babak Saboury
Publikováno v:
PET Clinics. 17:145-174
Malignant lymphomas are a family of heterogenous disorders caused by clonal proliferation of lymphocytes. 18F-FDG-PET has proven to provide essential information for accurate quantification of disease burden, treatment response evaluation, and progno
Autor:
Eliot L. Siegel, Babak Saboury, Navid Hasani, Michael A. Morris, Elizabeth C. Jones, Arman Rhamim, Ronald M. Summers
Publikováno v:
PET Clin
Trust in artificial intelligence (AI) by society and the development of trustworthy AI systems and ecosystems are critical for the progress and implementation of AI technology in medicine. With the growing use of AI in a variety of medical and imagin
Autor:
Sriram S Paravastu, Michael T. Collins, Ronald M. Summers, Faraz Farhadi, Babak Saboury, Lars Edenbrandt, Navid Hasani
Publikováno v:
PET Clinics. 17:115-135
This review discusses the current state of artificial intelligence (AI) in 18F-NaF-PET/CT imaging and the potential applications to come in diagnosis, prognostication, and improvement of care in patients with bone diseases, with emphasis on the role
Publikováno v:
PET Clinics. 17:31-39
Artificial intelligence (AI) can enhance the efficiency of medical imaging quality control and clinical documentation, provide clinical decision support, and increase image acquisition and processing quality. A clear understanding of the basic tenets
Autor:
Liangchen Liu, Jianfei Liu, Manas Kumar Nag, Navid Hasani, Seung Yeon Shin, Sriram S. Paravastu, Babak Saboury, Jing Xiao, Lingyun Huang, Ronald M. Summers
Publikováno v:
Multiscale Multimodal Medical Imaging ISBN: 9783031188138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb28cff735ae773d2059a16b6ff13c3b
https://doi.org/10.1007/978-3-031-18814-5_12
https://doi.org/10.1007/978-3-031-18814-5_12
Autor:
Navid, Hasani, Sriram S, Paravastu, Faraz, Farhadi, Fereshteh, Yousefirizi, Michael A, Morris, Arman, Rahmim, Mark, Roschewski, Ronald M, Summers, Babak, Saboury
Publikováno v:
PET Clin
Malignant lymphomas are a family of heterogenous disorders caused by clonal proliferation of lymphocytes. (18)F-FDG-PET has proven to provide essential information for accurate quantification of disease burden, treatment response evaluation, and prog